Related Experiment Video
Updated: Jun 5, 2025
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Mechanism of miRNAs and miRNA-mRNA Regulatory Networks in Modulating Drug Resistance in HER2-Positive Breast Cancer:
Thanh Hoa Vo1, Edel A McNeela1, Orla O'Donovan1
1Pharmaceutical and Molecular Biotechnology Research Center (PMBRC), Department of Science, South East Technological University, X91 K0EK Waterford, Ireland.
Background:
HER2-positive breast cancer is an aggressive subtype where innate/acquired resistance to targeted drugs remains a challenge. This study aims to uncover the underlying mechanisms of HER2 drug resistance through miRNA analysis and target identification.
Methods:
MiRNA datasets were systematically retrieved from the GEO database, and differential expression analysis was conducted for both miRNA and mRNA datasets. Functional analyses were also conducted to validate the identified miRNAs and assess their clinical relevance.
Results:
We identified 113 differentially expressed miRNAs (DEMs) and 923 target genes. Validation was performed using external mRNA datasets, and intersection with significant genes identified 110 overlapping genes associated with HER2 drug resistance. Further analyses included functional enrichment, construction of a protein-protein interaction (PPI) network, identification of key hub genes such as BCL2, FOS, and CXCR4, and assessment of clinical relevance through survival analysis and immunohistochemistry (IHC) assessments.
Conclusions:
This integrative approach unveils a complex landscape of HER2 drug resistance in breast cancer, identifying crucial miRNAs, target genes, and significant pathways. The findings offer novel insights into the mechanisms governing drug resistance and highlight the potential for enhancing therapeutic strategies. Future studies are necessary for experimental validation to further explore the complex mechanisms involved.
Insights
This study identifies key microRNAs (miRNAs) and genes driving resistance to HER2-targeted therapies in breast cancer. Understanding these mechanisms can help develop new strategies to overcome drug resistance.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- HER2-positive breast cancer presents significant therapeutic challenges due to drug resistance.
- Identifying mechanisms of resistance is crucial for improving treatment outcomes.
Purpose of the Study:
- To investigate the molecular mechanisms underlying drug resistance in HER2-positive breast cancer.
- To identify key microRNAs (miRNAs) and their target genes involved in resistance.
Main Methods:
- Systematic retrieval and analysis of miRNA and mRNA datasets from the GEO database.
- Differential expression analysis, functional enrichment, and protein-protein interaction network construction.
- Validation using external datasets and assessment of clinical relevance via survival analysis and immunohistochemistry.
Main Results:
- Identified 113 differentially expressed miRNAs (DEMs) and 923 target genes.
- Discovered 110 overlapping genes associated with HER2 drug resistance.
- Highlighted key hub genes including BCL2, FOS, and CXCR4.
Conclusions:
- An integrative approach revealed a complex network of miRNAs and genes contributing to HER2 drug resistance.
- Findings provide novel insights into resistance mechanisms and potential therapeutic targets.
- Further experimental validation is needed to explore these complex mechanisms.
Related Concept Videos
01:22MicroRNAs
02:56Treatment Resistant Cancers